Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis
NCT05098522
Hypersensitivity, Hypersensitivity, Immediate
London, United Kingdom
View Trial DetailsNCT Number: NCT01192386
Inflammatory proteins from eosinophil granulocytes in blood from patients with seasonal allergic hayfever have been shown to predict development of asthma at a six-year follow-up. This study is a 15-year follow-up of the same patients to verify earlier results and study disease development.
Looking for future studies?
Notify MeAll sexes
Observational
The study consists of a single visit at which patients fill in a questionnaire on actual hayfever and asthma symptoms as well as current treatment. Blood samples and nasal lavages are drawn and analysed for eosinophils as well as eosinophil cationic protein and tryptase. Spirometry is performed.
If patients use drugs which can interfere with results, ie. corticosteroids or beta-agonists, biochemistry and/or spirometry are omitted.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Single measurement - May 2010
Patients are asked whether they have experienced asthmatic symptoms or have been disgnosed with asthma within the latest 15 years
Time frame: Single measurement - May 2010
Patients are asked for current hayfever symptoms
Looking for future studies?
Notify MeUniversity of Aarhus
Other
Eosinophil Markers and Development of Disease in Allergic Rhinitis. A 15-year Follow-up of Patients With Grass Pollen Induced Hayfever.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05098522
Hypersensitivity, Hypersensitivity, Immediate
London, United Kingdom
View Trial DetailsNCT06837233
Hypersensitivity, Hypersensitivity, Immediate
Beijing, Beijing Municipality, China
View Trial DetailsNCT07091357
Hypersensitivity, Hypersensitivity, Immediate
Beijing, Beijing Municipality, China
View Trial DetailsNCT05346718
Allergic Rhinitis, Birch Pollen Allergy
Hanover, Lower Saxony, Germany
View Trial Details